Materiały źródłowe

• #1 Restricted growth (dwarfism)

  https://www.nhs.uk/conditions/restricted-growth/

  The main treatment for restricted growth is growth hormone medicine. […] Surgery to increase the length of your arms or legs is sometimes done, but this is rare. […] Growth hormone is used to increase height in children with restricted growth, or children who are not growing as expected for their age. […] It can treat many different types of restricted growth, but it is not normally used to treat a problem with bone development (such as achondroplasia and other skeletal dysplasias). […] Growth hormone medicines include: somatropin a daily injection used to treat many causes of restricted growth, somatrogon a weekly injection, only used if you have a lack of growth hormone (growth hormone deficiency). […] How well treatment works depends on what’s causing the restricted growth. Treatment usually continues until your child stops growing or reaches their target height.

• #1 Dwarfism – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/dwarfism/diagnosis-treatment/drc-20371975

  The goal of treatment is to keep you doing what you want to do independently. Most dwarfism treatments don’t increase stature, but they may correct or ease problems caused by complications. […] In 2021, the U.S. Food and Drug Administration (FDA) approved vosoritide, known by the brand name Voxzogo, to improve growth in children who have the most common type of dwarfism. Given as a shot, this medicine is for children 5 years of age and older who have achondroplasia and open growth plates so they can still grow. In studies, those who took Voxzogo grew an average of 0.6 inches (1.6 cm). Ask your doctor and geneticist about the potential risks and benefits. […] For people with dwarfism due to low levels of growth hormones, treatment with shots of a synthetic version of the hormone may increase final height. In most cases, children receive daily shots for several years until they reach a maximum adult height often within the average adult range for their families.

• #1 Restricted growth (dwarfism) – Treatment | Health Information from Newtons Chemist

  https://newtonschemist.co.uk/nhs_conditions_restricted-growth_treatment

  Some people with restricted growth (dwarfism) may be able to have growth hormone treatment or leg-lengthening surgery. […] The National Institute for Health and Care Excellence (NICE) recommends a human growth hormone treatment called somatropin as an option for children whose poor growth is linked to: growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease, a genetic condition called SHOX deficiency. […] NICE also recommends it for some children who are born small and fail to catch up in growth by the age of 4 or later. […] Somatropin treatment should be started and monitored by a child health specialist with expertise in managing growth hormone disorders in children (paediatric endocrinologist). […] The hormone is given as a single daily injection, which can usually be done by a parent, carer, or by the child when they’re old enough.

• #1 Restricted growth (dwarfism) – Treatment | Health Information from Newtons Chemist

  https://newtonschemist.co.uk/nhs_conditions_restricted-growth_treatment

  Skin reactions are the most commonly reported side effect. In very rare cases, the treatment is associated with persistent severe headaches, vomiting and vision problems. […] Children with growth hormone deficiency respond very well to somatropin and may be able to reach a relatively normal adult height. The effectiveness in children with other conditions can vary. […] Somatropin treatment may stop once your child stops growing, but in some cases it may be given into adulthood because it can sometimes help prevent problems such as weak bones (osteoporosis). […] NICE also recommends a growth hormone treatment called somatrogon for children and young people aged 3 to 17 years old with poor growth caused by growth hormone deficiency. […] It works in a similar way to somatropin but is given as a weekly injection instead of a daily one.

• #1 Dwarfism – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK563282/

  The normal variants of short stature can expect to lead healthy lives. The patients suffering from GHD can benefit from recombinant human growth hormone therapy and generally attain heights similar to their parents, given that the treatment is commenced before puberty. […] Short stature may be an indicator of chronic occult disease and need a thorough workup. […] The complications which are associated with GH therapy are- possible predisposition to type-2 diabetes, benign intracranial hypertension, edema/carpal tunnel syndrome, slipped capital femoral epiphysis (SCFE), scoliosis, prepubertal gynecomastia. Management of these complications can be done by temporary therapy termination until resolving symptoms and restarting later at lower doses.

• #1 New treatment for people with dwarfism | European Medicines Agency (EMA)

  https://www.ema.europa.eu/en/news/new-treatment-people-dwarfism

  EMA has recommended granting a marketing authorisation in the European Union (EU) for Voxzogo (vosoritide) for the treatment of achondroplasia, a condition that impairs bone growth and causes dwarfism. The medicine is intended for use in patients 2 years and older whose epiphyses (growth plates of the bones) are not yet closed. […] In patients with achondroplasia the fibroblast growth-factor receptor 3 (FGFR3) gene is permanently switched on, preventing normal bone growth. Vosoritide, the active substance in Voxzogo, works by attaching to a receptor called natriuretic peptide receptor type B (NPR-B) on the surface of cells. The activation of this receptor will reduce the activity of FGFR3 and thereby stimulate the normal growth of bones and improve the symptoms of the disease. […] During the course of the study, a statistically significant improvement in growth was observed in patients treated with vosoritide compared to placebo, adding an average 1.57 cm in height after a year of treatment. The observed increase in growth occurred proportionally in both the spine and the lower limbs. Longer-term data in number of patients suggest that the improved growth is maintained. A separate ongoing study including subjects aged 2 to 5 also suggests consistent improvement in growth.

• #1 FDA approval grows use of growth therapy for children with achondroplasia  – CHOC Pediatrica

  https://care.choc.org/fda-approval-grows-use-of-growth-therapy-for-children-with-achondroplasia/

  The most common type of dwarfism, achondroplasia can now be treated with Voxzogo starting at birth, maximizing children’s growth potential. […] In November 2021, the FDA approved Voxzogo (vosoritide) to assist with linear growth in children ages 5 and older with achondroplasia whose growth plate remained open. At the end of 2023, the FDA extended approval to children of all ages with achondroplasia with open growth plates. […] Starting earlier, then, signifies a large step toward helping children with achondroplasia reach their growth potential. […] After a child receives a diagnosis of achondroplasia, the newly updated approval permits them to begin a regimen of Voxzogo at any age. Administered daily via subcutaneous injection, Voxzogo affects linear growth by working on the growth plates of the endochondral bone — primarily long bones.

• #1 FDA approval grows use of growth therapy for children with achondroplasia  – CHOC Pediatrica

  https://care.choc.org/fda-approval-grows-use-of-growth-therapy-for-children-with-achondroplasia/

  Exciting as these numbers are, Dr. Bhangoo has treated patients who experienced substantially more improvement. […] To keep the growth plates open as long as possible, pediatric endocrinologists prescribe aromatase inhibitors. […] The goal of Voxzogo use is improved linear growth or height in patients that permits them to engage in normal, independent daily living. […] Thus far, clinicians have reported each of these improvements at various times. Preliminary data indicates that earlier treatment improves proportionate growth of the extremities while reducing spinal thoracolumbar kyphosis and genu varum. […] There is continual work to develop longer-acting subcutaneous formulation and other agents that can be taken orally for treatment of achondroplasia.

• #1 New Achondroplasia treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=97

  Clinical trials have demonstrated that Voxzogo significantly increases growth velocity, leading to improved height outcomes in children with achondroplasia. […] Limb-lengthening surgery is an invasive procedure aimed at increasing limb length and overall stature in individuals with achondroplasia. […] Although effective in significantly increasing height, limb-lengthening surgery carries risks such as infection, nerve damage, and prolonged recovery periods. […] Growth hormone therapy has been utilized off-label to attempt to improve growth velocity in children with achondroplasia. […] However, clinical evidence supporting its efficacy is limited and inconsistent. […] Several experimental treatments are currently under clinical investigation for achondroplasia. Infigratinib, an oral FGFR inhibitor, is undergoing clinical trials to assess its potential to improve growth velocity and bone development.

• #1 Gene therapy: A potential cure for growth-hormone resistant dwarfism

  https://www.drugtargetreview.com/news/103053/gene-therapy-a-potential-cure-for-growth-hormone-resistant-dwarfism/

  Researchers have shown that gene therapy using a single-dose injection of a virus carrying the good gene could possibly be used to cure growth-hormone resistant dwarfism. […] A new study from the NUS Yong Loo Lin School of Medicine (NUS Medicine), Singapore has shown that gene therapy using a single-dose injection of a virus carrying the good gene can potentially be used to cure growth-hormone resistant dwarfism, also known as Laron Syndrome. […] The team attempted to increase a hormone called insulin-like-growth factor 1 (IGF1) in a laboratory model by replacing the defective growth hormone receptor gene, using a virus containing instructions specifically targeted at the liver. […] The results showed the significant size and weight which increased steadily throughout the course of 26 weeks, in comparison to the untreated laboratory model.

• #1 Gene therapy: A potential cure for growth-hormone resistant dwarfism

  https://www.drugtargetreview.com/news/103053/gene-therapy-a-potential-cure-for-growth-hormone-resistant-dwarfism/

  Other researchers have shown that there is persistent gene expression for up to 10 years to produce proteins in the liver necessary for growth, following a single dose of AAV administration. This makes AAV gene therapy an attractive treatment with potentially significantly good therapy outcomes. […] With these optimistic results, the AAV vector can be potentially used to treat people with Laron syndrome. […] Gene therapy has given us a promising start in managing dwarfism. This is far more favourable compared to rhIGF1 injections, once or twice daily for many years, which causes side effects of pain and discomfort to patients and comes as a huge financial burden to those involved, concluded Professor Lee K O, research lead.

• #1 Restricted growth (dwarfism) – Treatment | Health Information from Newtons Chemist

  https://newtonschemist.co.uk/nhs_conditions_restricted-growth_treatment

  Common side effects of somatrogon include headaches, a high temperature and anaemia. It may not be a suitable treatment for all children. A child health specialist will advise you. […] If you have particularly short legs, a leg-lengthening process known as distraction may be an option. […] Using surgery, the leg bone is broken and fixed to a special frame. With the support of the frame, the leg is stretched, allowing new bone to form in between the two broken ends of bone. […] Over time, this bone gets stronger until it’s able to support your weight. […] Distraction can sometimes result in a significant increase in height, but it’s a lengthy treatment and has a risk of complications, so isn’t always recommended. […] Some people have pain during or after the limb-lengthening procedure.

• #1 Restricted growth (dwarfism) – Treatment | Health Information from Newtons Chemist

  https://newtonschemist.co.uk/nhs_conditions_restricted-growth_treatment

  Other possible complications include: poor bone formation, fracture, infection, bone lengthening at an inappropriate rate, blood clots. […] There’s also some uncertainty about the safety and effectiveness of the procedure. […] It’s therefore important that you understand exactly what it involves and talk to your surgeon or doctor about the risks if it’s suggested as a possible treatment for you or your child. […] As restricted growth can be associated with several related conditions and problems, affected children and adults will be cared for by a multidisciplinary team of healthcare professionals. […] You may have regular check-ups with members of your care team so your health can be monitored and any problems that develop can be treated.

• #1 Dwarfism – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/dwarfism/diagnosis-treatment/drc-20371975

  Treatment for girls with Turner syndrome also requires estrogen and related hormone therapy to start puberty and lead to adult sexual development. Estrogen replacement therapy usually continues until the average age of menopause. […] Surgical procedures that may correct problems in people with disproportionate dwarfism include: Correcting the direction the bones grow in. Stabilizing and correcting the shape of the spine. Increasing the size of the opening in bones of the spine, called vertebrae, to ease pressure on the spinal cord. Placing a shunt to remove too much fluid around the brain also known as hydrocephalus if it occurs. […] Some people with dwarfism choose to undergo surgery called extended limb lengthening. This procedure is controversial because there are risks. Those with dwarfism are urged to wait to decide about limb lengthening until they’re old enough to participate in the decision. This approach is recommended because of the emotional and physical stress involved with multiple procedures. […] Regular checkups and ongoing care by a healthcare professional familiar with dwarfism can make quality of life better. Because there is a range of symptoms and complications, conditions are managed as they happen, such as tests and treatment for ear infections, spinal stenosis or sleep apnea.

• #1 Achondroplasia Treatment – MU Health Care – Columbia, MO

  https://www.muhealth.org/conditions-treatments/pediatrics/orthopaedics/skeletal-dysplasia/achondroplasia

  Surgical intervention is typically not necessary but may be needed if the patient experiences extremity pain or if a lateral thrust is observed. Surgery should be performed by an orthopaedic doctor that specializes in skeletal dysplasia and may include derotational osteotomy or 8-plate. […] If treatment is required, a subocciptal decompression is necessary to relieve the compression of the respiratory centers and nerves. […] Treatment can include oxygen supplementation (used in a small percentage of patients) or a cervical decompression to treat foramen magnum compression. […] If serious obstructive sleep apnea is suspected, then polysomnography should be obtained for further information. There are several options for treatment, depending on the severity of the apnea: Adenoidectomy and/or tonsillectomy, CPAP machine use, BIPAP machine use.

• #1 Restricted growth (dwarfism)

  https://www.nhs.uk/conditions/restricted-growth/

  If you have a skeletal dysplasia such as achondroplasia, treatment usually aims to relieve any other symptoms you have, rather than increase your height. […] Treatments you may need include: physiotherapy for problems with movement and pain, orthodontics for problems with your teeth, treatment for ear infections and sleep apnoea, surgery, for example to straighten bowed legs, or to straighten or reduce pressure on your spine.

• #1 Dwarfism – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK563282/

  There are various treatment options available to these kids to achieve the best possible outcomes for them. These includes: […] Recombinant human growth hormone therapy (rhGH) is an effective treatment for patients suffering from growth hormone deficiency. Early intervention can prevent short stature and the psychosocial stress associated with it. […] For patients with idiopathic short stature (ISS), commencing GH therapy can enhance the growth velocity and mean adult height. […] Gonadotropin-releasing hormone (GnRH) analogs are used to halt the progression of precocious puberty. […] Brain tumors need neurosurgery intervention. The limb-lengthening procedures are not recommended as they have high morbidity and mortality. […] The child receives daily subcutaneous growth hormone (GH) injections, and are advised to take GH injections regularly, preferably within 1 hour of sleep every night, at a specific time, and not to miss more than one dose a month.

• #1 Treatment of Dwarfism With Recombinant Human Insulin-Like Growth Factor-1

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2780013/

  In 2007 the European Medicines Agency (EMEA) licensed the use of recombinant (rh) IGF-1 (mecasermin) for the treatment of dwarfism in severe primary IGF-1 deficiency. […] Treatment with IGF-1 is the only effective therapeutic option in such cases. […] Experiences with treatment with rhIGF-1 for dwarfism in severe primary IGF-1 deficiency date back to the early 1990s. […] The results with regard to growth in the short term and long term (47 years) are remarkably consistent. […] Replacement therapy with IGF-1 in children with severe primary IGF-1 deficiencywhich is rare, with a prevalence of 1:10 000is the pathophysiologically correct form of treatment, for which there is currently no alternative. […] The treatment has been found to be relatively safe for patients, even though they have to be treated over many years.

• #1 Treatment of Dwarfism With Recombinant Human Insulin-Like Growth Factor-1

  https://pmc.ncbi.nlm.nih.gov/articles/PMC2780013/

  The growth hormone-IGF (insulin-like growth factor) system plays a central role in hormonal growth regulation. Recombinant human (rh) growth hormone (GH) has been available since the late 1980s for replacement therapy in GH-deficient patients and for the stimulation of growth in patients with short stature of various causes. Growth promotion by GH occurs in part indirectly through the induction of IGF-1 synthesis. In primary disturbances of IGF-1 production, short stature can only be treated with recombinant human IGF-1 (rhIGF-1). rhIGF-1 was recently approved for this indication but can also be used to treat other conditions. […] In children with severe primary IGF-1 deficiency (a rare condition whose prevalence is less than 1:10 000), the prognosis for final height is very poor (ca. 130 cm), and IGF-1 therapy is the appropriate form of pathophysiologically based treatment. There is no alternative treatment at present. The subcutaneous administration of IGF-1 twice daily in doses of 80 to 120 g/kg accelerates growth and increases final height by 12 to 15 cm, according to current data.

• #1 A new daily tablet increases growth in children with dwarfism, study finds – India Today

  https://www.indiatoday.in/health/story/a-new-daily-tablet-increases-growth-in-children-with-dwarfism-study-finds-2635835-2024-11-19

  A new daily tablet has shown promise in boosting growth and improving limb proportions in children with achondroplasia, the most common form of dwarfism, according to a study. […] Over an 18-month treatment period, the childrens growth rate increased by an average of 2.5 cm per year. The drug also improved the proportionality of their upper and lower body segments. […] „Infigratinib not only enhances bone growth but also improves the quality of life for children with achondroplasia. It offers a much-needed oral alternative for those unable to tolerate injections and in regions where oral medication is more feasible.” […] For families dealing with achondroplasia, this new oral therapy offers hope for a more convenient and effective solution to improve growth and overall well-being, the researchers said.

• #1 Short Stature | Children’s Hospital Colorado

  https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/short-stature/

  Growth hormone treatment isn’t right for everyone. It is appropriate for children who: […] Some children may experience side effects from growth hormone injections, especially if they don’t have growth hormone deficiency. We will discuss these side effects with your family before starting therapy. The sooner children begin treatment, the more likely they are to grow to a typical adult height. […] Our Department of Pediatric Endocrinology treats your child as an individual. We evaluate all their physical, radiology and laboratory findings to consider the best solutions for their unique needs. […] We offer a full range of medical, radiologic and surgical therapies. We also have nursing and medical support available for our patients 24 hours a day, 7 days a week.

• #2 Dwarfism – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/dwarfism/diagnosis-treatment/drc-20371975

  The goal of treatment is to keep you doing what you want to do independently. Most dwarfism treatments don’t increase stature, but they may correct or ease problems caused by complications. […] In 2021, the U.S. Food and Drug Administration (FDA) approved vosoritide, known by the brand name Voxzogo, to improve growth in children who have the most common type of dwarfism. Given as a shot, this medicine is for children 5 years of age and older who have achondroplasia and open growth plates so they can still grow. In studies, those who took Voxzogo grew an average of 0.6 inches (1.6 cm). Ask your doctor and geneticist about the potential risks and benefits. […] For people with dwarfism due to low levels of growth hormones, treatment with shots of a synthetic version of the hormone may increase final height. In most cases, children receive daily shots for several years until they reach a maximum adult height often within the average adult range for their families.

• #2 Dwarfism | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/dwarfism

  The goal of treatment is to keep you doing what you want to do independently. Most dwarfism treatments don’t increase stature, but they may correct or ease problems caused by complications. […] In 2021, the U.S. Food and Drug Administration (FDA) approved vosoritide, known by the brand name Voxzogo, to improve growth in children who have the most common type of dwarfism. Given as a shot, this medicine is for children 5 years of age and older who have achondroplasia and open growth plates so they can still grow. In studies, those who took Voxzogo grew an average of 0.6 inches (1.6 cm). Ask your doctor and geneticist about the potential risks and benefits. […] For people with dwarfism due to low levels of growth hormones, treatment with shots of a synthetic version of the hormone may increase final height. In most cases, children receive daily shots for several years until they reach a maximum adult height often within the average adult range for their families.

• #2 Dwarfism (Restricted Growth): Types and Causes

  https://patient.info/bones-joints-muscles/restricted-growth-dwarfism

  Dwarfism in itself is not a disease that needs a 'cure’. It is a condition which in some cases may be caused by a disease, so sometimes treatments may be needed. […] For most people with dwarfism, treatment for growth itself is not possible or helpful. Most people will adapt their way of life to cope with their less than average height, but otherwise lead entirely normal lives. […] Treatment that might be relevant includes: […] This is treatment with a hormone medicine which aims to replace the growth hormone normally produced by the body. This is only helpful in a few specific causes of dwarfism where the lack of growth is caused by a lack of growth hormone. It is not helpful for people with achondroplasia. It is a treatment recommended by and managed by a specialist doctor. […] Rarely, an operation may be done to lengthen the bones of the legs. This is not commonly done as it involves breaking the leg bones and is a lengthy treatment with a number of risks.

• #2

  https://111.wales.nhs.uk/encyclopaedia/r/article/restrictedgrowth

  Treatment for restricted growth may include growth hormone injections, which can help a child with the condition grow more than they otherwise would. […] In cases of DSS where the legs are particularly short, a leg-lengthening procedure is sometimes used, but there’s some uncertainty about its safety and effectiveness. […] Some people with restricted growth (dwarfism) may be able to have growth hormone treatment or leg-lengthening surgery. […] The National Institute for Health and Care Excellence (NICE) recommends human growth hormone treatment (somatropin) as an option for children whose poor growth is linked to growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease, or a genetic condition called SHOX deficiency. […] Somatropin treatment should be started and monitored by a child health specialist with expertise in managing growth hormone disorders in children (paediatric endocrinologist).

• #2 Treatment | NICS Well

  https://www.nicswell.co.uk/conditions-and-treatments/restricted-growth-dwarfism/treatment

  Some people with restricted growth (dwarfism) may be able to have growth hormone treatment or leg-lengthening surgery. […] NICE also recommends it for some children who are born small and fail to catch up in growth by the age of 4 or later. […] Somatropin treatment should be started and monitored by a child health specialist with expertise in managing growth hormone disorders in children (paediatric endocrinologist). […] Children with growth hormone deficiency respond very well to somatropin and may be able to reach a relatively normal adult height. […] Somatropin treatment may stop once your child stops growing, but in some cases it may be given into adulthood because it can sometimes help prevent problems such as weak bones (osteoporosis). […] If you have particularly short legs, a leg-lengthening process known as distraction may be an option.

• #2 Restricted growth (dwarfism) – Treatment | Health Information from Newtons Chemist

  https://newtonschemist.co.uk/nhs_conditions_restricted-growth_treatment

  Skin reactions are the most commonly reported side effect. In very rare cases, the treatment is associated with persistent severe headaches, vomiting and vision problems. […] Children with growth hormone deficiency respond very well to somatropin and may be able to reach a relatively normal adult height. The effectiveness in children with other conditions can vary. […] Somatropin treatment may stop once your child stops growing, but in some cases it may be given into adulthood because it can sometimes help prevent problems such as weak bones (osteoporosis). […] NICE also recommends a growth hormone treatment called somatrogon for children and young people aged 3 to 17 years old with poor growth caused by growth hormone deficiency. […] It works in a similar way to somatropin but is given as a weekly injection instead of a daily one.

• #2 Dwarfism – MD Searchlight

  https://mdsearchlight.com/genetic-disorders/dwarfism/

  There are several treatment options available to children to help them achieve the best possible outcomes. These include: […] Recombinant human growth hormone therapy (rhGH) is a good treatment for children who aren’t growing as they should be due to a lack of certain hormones. Starting this treatment early can help prevent them from being much shorter than their peers and dealing with the mental stress that can come with it. […] Gonadotropin-releasing hormone (GnRH) analogs are used to stop the progress of early-onset puberty. […] Hormone therapy to help kids grow can sometimes have complications, such as the potential for developing type-2 diabetes, benign pressure increase in the skull, water retention or carpal tunnel syndrome, displacement of the growth plate in the hip joint, scoliosis, and swelling of the breast tissue in boys before puberty begins.

• #2 Restricted growth: hope, fear as a new drug challenges dwarfism attitudes

  https://www.pharmaceutical-technology.com/features/dwarfism-drug-biomarin/

  BioMarins vosoritide could become the worlds first treatment to address the underlying cause of achondroplasia, the most common form of dwarfism. […] Currently there is no approved therapeutic available to treat the genetic basis of achondroplasia, with medical and surgical interventions limited to addressing some of the symptoms of the condition, including spinal stenosis, hydrocephalus and obstructive sleep apnoea. […] In recent years, however, a novel therapeutic avenue has emerged to potentially address the underlying genetic mutation that causes achondroplasia. […] This longer-lasting protein became vosoritide, the companys investigational drug for achondroplasia, delivered via once-daily subcutaneous injections. […] Over the last five years or so, BioMarin has been pursuing a broad clinical programme to build a convincing evidence base for the safety and efficacy of vosoritide, which has been granted orphan drug designation from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• #2 New treatment for people with dwarfism | European Medicines Agency (EMA)

  https://www.ema.europa.eu/en/news/new-treatment-people-dwarfism

  EMA has recommended granting a marketing authorisation in the European Union (EU) for Voxzogo (vosoritide) for the treatment of achondroplasia, a condition that impairs bone growth and causes dwarfism. The medicine is intended for use in patients 2 years and older whose epiphyses (growth plates of the bones) are not yet closed. […] In patients with achondroplasia the fibroblast growth-factor receptor 3 (FGFR3) gene is permanently switched on, preventing normal bone growth. Vosoritide, the active substance in Voxzogo, works by attaching to a receptor called natriuretic peptide receptor type B (NPR-B) on the surface of cells. The activation of this receptor will reduce the activity of FGFR3 and thereby stimulate the normal growth of bones and improve the symptoms of the disease. […] During the course of the study, a statistically significant improvement in growth was observed in patients treated with vosoritide compared to placebo, adding an average 1.57 cm in height after a year of treatment. The observed increase in growth occurred proportionally in both the spine and the lower limbs. Longer-term data in number of patients suggest that the improved growth is maintained. A separate ongoing study including subjects aged 2 to 5 also suggests consistent improvement in growth.

• #2 A new daily tablet increases growth in children with dwarfism, study finds – India Today

  https://www.indiatoday.in/health/story/a-new-daily-tablet-increases-growth-in-children-with-dwarfism-study-finds-2635835-2024-11-19

  A new daily tablet has shown promise in boosting growth and improving limb proportions in children with achondroplasia, the most common form of dwarfism, according to a study. […] Over an 18-month treatment period, the childrens growth rate increased by an average of 2.5 cm per year. The drug also improved the proportionality of their upper and lower body segments. […] „Infigratinib not only enhances bone growth but also improves the quality of life for children with achondroplasia. It offers a much-needed oral alternative for those unable to tolerate injections and in regions where oral medication is more feasible.” […] For families dealing with achondroplasia, this new oral therapy offers hope for a more convenient and effective solution to improve growth and overall well-being, the researchers said.

• #2 New Achondroplasia treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=97

  Voxzogo represents a significant advancement as an FDA-approved medication targeting growth impairment; however, it does not address all clinical manifestations of achondroplasia. […] Experimental treatments such as infigratinib, recifercept, and gene therapy approaches hold promise but require further research and clinical validation. […] Management of achondroplasia primarily involves symptomatic treatments aimed at addressing complications and improving quality of life. […] Current therapies, including vosoritide, primarily target growth velocity and height improvement but do not fully address other common complications associated with achondroplasia, such as spinal stenosis, joint abnormalities, and neurological complications. […] A comprehensive and multidisciplinary approach remains essential in managing achondroplasia effectively.

• #2

  https://111.wales.nhs.uk/encyclopaedia/r/article/restrictedgrowth

  If you have particularly short legs, a leg-lengthening process known as distraction may be an option. […] Distraction can sometimes result in a significant increase in height, but it’s a lengthy treatment and has a risk of complications, so isn’t always recommended. […] It’s therefore important that you understand exactly what it involves and talk to your surgeon or doctor about the risks if it’s suggested as a possible treatment for you or your child.

• #2 Dwarfism – EM Doctors

  https://em-doctors.com/conditions/restricted-growth/

  If you have particularly short legs, a leg-lengthening process known as distraction may be an option. […] Distraction can sometimes result in a significant increase in height, but it’s a lengthy treatment and has a risk of complications, so isn’t always recommended. […] It’s therefore important that you understand exactly what it involves and talk to your surgeon or doctor about the risks if it’s suggested as a possible treatment for you or your child.

• #2 Treatment | NICS Well

  https://www.nicswell.co.uk/conditions-and-treatments/restricted-growth-dwarfism/treatment

  Distraction can sometimes result in a significant increase in height, but it’s a lengthy treatment and has a risk of complications, so isn’t always recommended. […] It’s therefore important that you understand exactly what it involves and talk to your surgeon or doctor about the risks if it’s suggested as a possible treatment for you or your child.

• #2 Dwarfism | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/dwarfism

  Treatment for girls with Turner syndrome also requires estrogen and related hormone therapy to start puberty and lead to adult sexual development. Estrogen replacement therapy usually continues until the average age of menopause. […] Surgical procedures that may correct problems in people with disproportionate dwarfism include: Correcting the direction the bones grow in. Stabilizing and correcting the shape of the spine. Increasing the size of the opening in bones of the spine, called vertebrae, to ease pressure on the spinal cord. Placing a shunt to remove too much fluid around the brain also known as hydrocephalus if it occurs. […] Regular checkups and ongoing care by a healthcare professional familiar with dwarfism can make quality of life better. Because there is a range of symptoms and complications, conditions are managed as they happen, such as tests and treatment for ear infections, spinal stenosis or sleep apnea.

• #2 Dwarfism (Restricted Growth): Types and Causes

  https://patient.info/bones-joints-muscles/restricted-growth-dwarfism

  For a person with an unusual syndrome resulting in a number of medical problems, often a team of health professionals is involved to help. […] In many countries there are websites for support groups with more information for people either with dwarfism or with the specific conditions causing it. Some of those in the UK are listed in the further reading section below.

• #2 Dwarfism – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/dwarfism/diagnosis-treatment/drc-20371975

  Treatment for girls with Turner syndrome also requires estrogen and related hormone therapy to start puberty and lead to adult sexual development. Estrogen replacement therapy usually continues until the average age of menopause. […] Surgical procedures that may correct problems in people with disproportionate dwarfism include: Correcting the direction the bones grow in. Stabilizing and correcting the shape of the spine. Increasing the size of the opening in bones of the spine, called vertebrae, to ease pressure on the spinal cord. Placing a shunt to remove too much fluid around the brain also known as hydrocephalus if it occurs. […] Some people with dwarfism choose to undergo surgery called extended limb lengthening. This procedure is controversial because there are risks. Those with dwarfism are urged to wait to decide about limb lengthening until they’re old enough to participate in the decision. This approach is recommended because of the emotional and physical stress involved with multiple procedures. […] Regular checkups and ongoing care by a healthcare professional familiar with dwarfism can make quality of life better. Because there is a range of symptoms and complications, conditions are managed as they happen, such as tests and treatment for ear infections, spinal stenosis or sleep apnea.

• #2 Restricted growth (dwarfism)

  https://www.nhs.uk/conditions/restricted-growth/

  If you have a skeletal dysplasia such as achondroplasia, treatment usually aims to relieve any other symptoms you have, rather than increase your height. […] Treatments you may need include: physiotherapy for problems with movement and pain, orthodontics for problems with your teeth, treatment for ear infections and sleep apnoea, surgery, for example to straighten bowed legs, or to straighten or reduce pressure on your spine.

Zobacz więcej